RESPIRERX PHARMACEUTICALS INC.: 10-Q filed 2022-11-17

Name: RESPIRERX PHARMACEUTICALS INC.: 10-Q filed 2022-11-17
Creator: RESPIRERX PHARMACEUTICALS INC.
License: https://creativecommons.org/licenses/by/4.0/

What RESPIRERX PHARMACEUTICALS INC. reported in its quarterly report filed 2022-11-17 (fiscal Q3 2022): 21 published measures, 67 facts as tagged in accession 0001493152-22-032757.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-17
Fiscal period: fiscal Q3 2022
Accession: 0001493152-22-032757 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All RESPIRERX PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	50,603	USD
At 2021-12-31	208,737	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	11,641,232	USD
At 2021-12-31	10,216,495	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	-11,590,629	USD
At 2022-06-30	-11,131,459	USD
At 2022-03-31	-10,867,921	USD
At 2021-12-31	-10,007,758	USD
At 2021-09-30	-9,424,888	USD
At 2021-06-30	-8,816,881	USD
At 2021-03-31	-8,454,618	USD
At 2020-12-31	-8,063,320	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-09-30	60	USD
At 2021-12-31	1,398	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-472,578	USD	92
2022-01-01 to 2022-09-30	-1,813,029	USD	273
2022-04-01 to 2022-06-30	-480,288	USD	91
2022-01-01 to 2022-03-31	-860,163	USD	90
2021-07-01 to 2021-09-30	-708,682	USD	92
2021-01-01 to 2021-09-30	-2,371,145	USD	273
2021-04-01 to 2021-06-30	-812,214	USD	91
2021-01-01 to 2021-03-31	-850,249	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-155,061	USD	273
2021-01-01 to 2021-09-30	-800,622	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	153,723	USD	273
2021-01-01 to 2021-09-30	800,353	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-175,768,165	USD
At 2021-12-31	-173,955,136	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	119,264,928	shares	92
2022-01-01 to 2022-09-30	107,816,034	shares	273
2021-07-01 to 2021-09-30	90,396,596	shares	92
2021-01-01 to 2021-09-30	83,757,619	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.01	USD/shares	92
2022-01-01 to 2022-09-30	-0.03	USD/shares	273
2021-07-01 to 2021-09-30	-0.01	USD/shares	92
2021-01-01 to 2021-09-30	-0.03	USD/shares	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-388,966	USD	92
2022-01-01 to 2022-09-30	-1,358,393	USD	273
2021-07-01 to 2021-09-30	-581,309	USD	92
2021-01-01 to 2021-09-30	-2,045,446	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	50,603	USD
At 2021-12-31	208,737	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	11,437,232	USD
At 2021-12-31	9,922,495	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	388,966	USD	92
2022-01-01 to 2022-09-30	1,358,393	USD	273
2021-07-01 to 2021-09-30	581,309	USD	92
2021-01-01 to 2021-09-30	2,045,446	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	138,050	USD	92
2022-01-01 to 2022-09-30	400,307	USD	273
2021-07-01 to 2021-09-30	157,751	USD	92
2021-01-01 to 2021-09-30	550,343	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	119,594,276	shares
At 2021-12-31	97,894,276	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-09-30	164,036,239	USD
At 2021-12-31	163,827,781	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-1,642,172	USD	92
2022-01-01 to 2022-09-30	-3,333,361	USD	273
2021-07-01 to 2021-09-30	-1,086,724	USD	92
2021-01-01 to 2021-09-30	-2,749,187	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	250,916	USD	92
2022-01-01 to 2022-09-30	958,086	USD	273
2021-07-01 to 2021-09-30	423,558	USD	92
2021-01-01 to 2021-09-30	1,495,103	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	10,308	USD	273
2021-01-01 to 2021-09-30	6,653	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2021-01-01 to 2021-09-30	117,299	USD	273

Inspect the source

Entity: RESPIRERX PHARMACEUTICALS INC. / CIK 0000849636
Captured: 2026-09-22 19:31 UTC
SEC response SHA-256: f692532c7d166963e2fad68da28689f5b935e4c0402c22ccfa62bc8615c926ab

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000849636.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))